{
    "organizations": [],
    "uuid": "925936fcb1785c402b1a2b07fbc2081b1a3fd3b4",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-azurrx-biopharma-announces-positiv/brief-azurrx-biopharma-announces-positive-preclinical-data-with-azx1103-idUSFWN1RV0JT",
    "ord_in_thread": 0,
    "title": "BRIEF-Azurrx Biopharma Announces Positive Preclinical Data With AZX1103",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "April 18 (Reuters) - AzurRx BioPharma Inc:\n* AZURRX BIOPHARMA ANNOUNCES POSITIVE PRECLINICAL DATA WITH AZX1103\n* AZURRX BIOPHARMA INC - AZX1103 SHOWN TO BE SAFE AND BIOLOGICALLY ACTIVE IN A WELL-ESTABLISHED PRE-CLINICAL MODEL\n* AZURRX BIOPHARMA - PRECLINICAL STUDIES INVESTIGATED ORAL DELIVERY OF AZ1103 USING THREE CAPSULE FORMULATIONS, ALL APPEARING TO BE WELL TOLERATED Source text for Eikon: Further company coverage:\n ",
    "published": "2018-04-18T20:00:00.000+03:00",
    "crawled": "2018-04-19T14:58:00.011+03:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "april",
        "reuters",
        "azurrx",
        "biopharma",
        "inc",
        "azurrx",
        "biopharma",
        "announces",
        "positive",
        "preclinical",
        "data",
        "azx1103",
        "azurrx",
        "biopharma",
        "inc",
        "azx1103",
        "shown",
        "safe",
        "biologically",
        "active",
        "model",
        "azurrx",
        "biopharma",
        "preclinical",
        "study",
        "investigated",
        "oral",
        "delivery",
        "az1103",
        "using",
        "three",
        "capsule",
        "formulation",
        "appearing",
        "well",
        "tolerated",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}